Medical Condition News

RSS

Pten gene can also fight against obesity, ageing process

This result, obtained after five years' research, is published in leading journal Cell Metabolism. The authors, led by Manuel Serrano (CNIO), believe it will open the door to new therapeutic options not only against cancer, but against obesity and even the ageing process.

7 Mar 2012

Scientists develop nanocombinatorics for directing stem cell differentiation

Northwestern University scientists have developed a powerful analytical method that they have used to direct stem cell differentiation. Out of millions of possibilities, they rapidly identified the chemical and physical structures that can cue stem cells to become osteocytes, cells found in mature bone.

7 Mar 2012

First study to demonstrate cost-effectiveness of intensive TBI care

Aggressive treatment for severe traumatic brain injuries costs more than routine care, yet yields significantly better outcomes, improved quality of life, and lower long term care costs, according to a new study by researchers in the Perelman School of Medicine at the University of Pennsylvania.

7 Mar 2012

Timely treatment with Berinert provides faster symptom relief for HAE patients

CSL Behring announced today that treatment with Berinert, C1 Esterase Inhibitor (Human) within six hours of the onset of an acute hereditary angioedema (HAE) attack provides faster symptom relief than later treatment, according to data presented at the 2012 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

7 Mar 2012

Researchers reveal how melanoma develops resistance to Zelboraf

Cancer is tough to kill and has many ways of evading the drugs used by oncologists to try and eliminate it. Now, researchers at UCLA's Jonsson Comprehensive Cancer Center have uncovered how an advanced form of melanoma gets around an inhibitor, Zelboraf, which targets the mutated BRAF gene.

7 Mar 2012

Shire to commence two Vyvanse and Concerta Phase 4 comparison trials for ADHD

As part of its continued commitment to ADHD research, Shire plc, the global specialty biopharmaceutical company, today announced it is initiating two Phase 4 clinical trials to compare Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) to Concerta (methylphenidate HCl) Extended-Release Tablets.

7 Mar 2012

People with schizophrenia benefit from new evidence-based clinical program

People with schizophrenia report improved functioning after participating in a new, evidence-based clinical program, according to results announced today from a six-month pilot.

7 Mar 2012

Tree nut consumption may reduce weight and health risks

March is National Nutrition Month and as the spotlight shines on all things healthy, celebrate with a mindful snack that loves you back-California pistachios.

7 Mar 2012

CU Cancer Center aims to make progress against squamous cell lung cancer

Recent advances in targeted cancer treatments greatly bolster the prognosis for many types of lung cancer, but according to a University of Colorado Cancer Center investigator, "practically nothing has improved in squamous cell lung cancer in the last decades."

7 Mar 2012

FDA issues Complete Response Letter to Eisai for Dacogen sNDA

Astex Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter to partner Eisai for their supplemental New Drug Application (sNDA) for Dacogen (decitabine) for Injection for patients with acute myeloid leukemia (AML) in adults 65 years of age or older who are not considered candidates for induction therapy.

7 Mar 2012

Altogen launches new pancreas-targeted in vivo RNAi transfection system

Altogen Biosystems announced the launch of its new pancreas-targeted in vivo RNAi transfection system in the company's popular in vivo delivery product line for use in laboratories and research facilities for development of new medicines and testing in cells and animals.

7 Mar 2012

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the company's ANTISENILIN monoclonal antibody platform technology for the treatment and prevention of Alzheimer's disease.

7 Mar 2012

Bevacizumab drug improves cardiac output in patients with HHT

In a small study that included 25 patients with hereditary hemorrhagic telangiectasia (a genetic disorder that leads to abnormalities of blood vessels) and severe liver involvement with this disease, patients who received the drug bevacizumab had improved cardiac output and a reduction in the duration and number of episodes of nose bleeds, a potentially life-threatening complication for patients with this disorder, according to a study in the March 7 issue of JAMA.

6 Mar 2012

Scripps scientists to develop new generation of broad spectrum anti-cancer therapeutics

A pair of Scripps Research Institute scientists, one a cancer biologist and the other a chemist, has been awarded $3.85 million from the National Institutes of Health (NIH) to develop a new generation of broad spectrum anti-cancer therapeutics, including breast cancer and lymphoma.

6 Mar 2012

Aggressive treatment of severe TBI is cost-effective: Study

Researchers at the Perelman School of Medicine at the University of Pennsylvania have demonstrated that aggressive treatment of severe traumatic brain injury, which includes invasive monitoring of intracranial pressure (ICP) and decompressive craniectomy, produces better patient outcomes than less aggressive measures and is cost-effective in patients no matter their age--even in patients 80 years of age.

6 Mar 2012

AcelRx initiates ARX-01 Phase 3 study for treatment of post-operative pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported dosing of the first patient in a Phase 3 study for ARX-01, the Sufentanil NanoTab PCA System, its novel sublingual patient-controlled analgesia system.

6 Mar 2012

Marriage boosts survival following coronary artery bypass surgery

Married adults who undergo heart surgery are more than three times as likely as single people who have the same surgery to survive the next three months, a new study finds.

6 Mar 2012

Blocking Plexin B1 protein can prevent formation of breast cancer metastases

In particularly aggressive forms of breast cancer, cancer cells can settle in other organs and form metastases there. Once such metastases form, complete recovery is rare. Consequently, it is enormously important to prevent the metastasisation of the breast cancer cells. The success, however, achieved by using existing forms of therapy is limited.

6 Mar 2012

Metabolic syndrome predicts prevalence and incidence of CKD in elderly people

Elderly people with the metabolic syndrome-defined as having multiple risk factors associated with developing diabetes and heart disease-had an increased risk of chronic kidney disease, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

6 Mar 2012

Study: Weekend smoking linked with memory damage

People who smoke only at weekends cause as much damage to their memory as those who smoke on a daily basis, according to research from Northumbria University.

6 Mar 2012